|

DemonsTTRate: A Global, Observational, Multicenter, Long-term Study of Patients With ATTR-CM in a Real-World Setting

RECRUITINGSponsored by Alnylam Pharmaceuticals
Actively Recruiting
SponsorAlnylam Pharmaceuticals
Started2026-01-09
Est. completion2030-10-23
Eligibility
Age18 Years+
Healthy vol.Accepted
Locations1 site
View on ClinicalTrials.gov →

NCT07358078

Summary

The purpose of this study is to: * Describe the clinical characteristics of adult patients with transthyretin-mediated amyloidosis with cardiomyopathy (ATTR-CM) treated with vutrisiran in routine clinical care * Describe treatment patterns of adult patients with ATTR-CM treated with vutrisiran in routine clinical care * Assess health-related quality of life (HRQOL) in adult patients with ATTR-CM treated with vutrisiran in routine clinical care * Assess healthcare resource use (HCRU) in adult patients with ATTR-CM treated with vutrisiran in routine clinical care Compare the long-term effectiveness of vutrisiran versus other approved ATTR-CM treatments in routine clinical care

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Has a diagnosis of ATTR-CM
* Is initiating treatment with vutrisiran or another approved ATTR-CM therapy

Exclusion Criteria:

* Is enrolled in an interventional clinical trial

Conditions2

Heart DiseaseTransthyretin Amyloidosis With Cardiomyopathy

Locations1 site

Clinical Trial Site
New Brunswick, New Jersey, 08901

Browse More Trials

Heart Disease trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.